loading
Precedente Chiudi:
$3.96
Aprire:
$4.25
Volume 24 ore:
2.26M
Relative Volume:
1.15
Capitalizzazione di mercato:
$290.72M
Reddito:
$31.25M
Utile/perdita netta:
$-88.48M
Rapporto P/E:
-2.6968
EPS:
-1.55
Flusso di cassa netto:
$-79.63M
1 W Prestazione:
+91.62%
1M Prestazione:
+245.24%
6M Prestazione:
+254.02%
1 anno Prestazione:
+369.32%
Intervallo 1D:
Value
$4.07
$4.55
Intervallo di 1 settimana:
Value
$2.03
$5.17
Portata 52W:
Value
$0.77
$5.17

Aclaris Therapeutics Inc Stock (ACRS) Company Profile

Name
Nome
Aclaris Therapeutics Inc
Name
Telefono
484-324-7933
Name
Indirizzo
701 LEE ROAD, WAYNE, PA
Name
Dipendente
91
Name
Cinguettio
@aclaristx
Name
Prossima data di guadagno
2024-11-18
Name
Ultimi documenti SEC
Name
ACRS's Discussions on Twitter

Confronta ACRS con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
ACRS 4.17 290.72M 31.25M -88.48M -79.63M -1.55
TMO 515.38 196.16B 42.37B 6.14B 7.78B 15.26
DHR 234.12 167.14B 23.74B 3.89B 4.98B 7.93
A 131.83 37.71B 6.50B 1.41B 1.42B 3.82
IQV 196.50 35.48B 15.32B 1.41B 1.96B 5.95
IDXX 414.71 33.75B 3.84B 866.24M 792.60M 9.80

Aclaris Therapeutics Inc Stock (ACRS) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2022-12-14 Iniziato Stifel Buy
2022-12-01 Iniziato Goldman Buy
2022-10-06 Iniziato BTIG Research Buy
2021-07-23 Ripresa Jefferies Buy
2021-06-15 Iniziato Piper Sandler Overweight
2021-04-21 Iniziato H.C. Wainwright Buy
2019-10-22 Aggiornamento SVB Leerink Mkt Perform → Outperform
2019-09-06 Downgrade JMP Securities Mkt Outperform → Mkt Perform
2019-06-27 Downgrade SVB Leerink Outperform → Mkt Perform
2019-05-06 Iniziato SVB Leerink Outperform
2018-03-28 Ripresa Leerink Partners Outperform
2018-02-09 Iniziato Guggenheim Buy
2017-06-16 Iniziato Cantor Fitzgerald Overweight
2016-11-29 Iniziato Leerink Partners Outperform
2016-09-30 Iniziato JMP Securities Mkt Outperform
2016-06-10 Iniziato Guggenheim Buy
2015-11-02 Iniziato Citigroup Buy
2015-11-02 Iniziato Jefferies Buy
Mostra tutto

Aclaris Therapeutics Inc Borsa (ACRS) Ultime notizie

pulisher
07:32 AM

Aclaris Therapeutics enters into exclusive license agreement for two drugs - Pennsylvania Business Report

07:32 AM
pulisher
07:10 AM

Equities Analysts Offer Predictions for ACRS FY2024 Earnings - MarketBeat

07:10 AM
pulisher
07:00 AM

Aclaris Therapeutics Secures Exclusive Licensing for Novel Antibody Therapies - MyChesCo

07:00 AM
pulisher
02:17 AM

Aclaris Therapeutics (NASDAQ:ACRS) Raised to “Strong-Buy” at Leerink Partnrs - Defense World

02:17 AM
pulisher
Nov 20, 2024

Aclaris Therapeutics director acquires $1.5 million in stock By Investing.com - Investing.com Canada

Nov 20, 2024
pulisher
Nov 20, 2024

Aclaris Therapeutics (NASDAQ:ACRS) Upgraded at Leerink Partnrs - MarketBeat

Nov 20, 2024
pulisher
Nov 20, 2024

Aclaris Therapeutics upgraded to Buy from Hold at Jefferies - MSN

Nov 20, 2024
pulisher
Nov 20, 2024

Aclaris Therapeutics (ACRS) Reports Q3 Loss, Misses Revenue Estimates - MSN

Nov 20, 2024
pulisher
Nov 20, 2024

S&P 500 Value (IVX) QuotePress Release - The Globe and Mail

Nov 20, 2024
pulisher
Nov 20, 2024

Aclaris signs license deal for biologics assets - MSN

Nov 20, 2024
pulisher
Nov 20, 2024

Aclaris stock soars for second day on licensing deal, analyst upgrades - MSN

Nov 20, 2024
pulisher
Nov 20, 2024

Aclaris Therapeutics (NASDAQ:ACRS) Rating Increased to Buy at BTIG Research - Defense World

Nov 20, 2024
pulisher
Nov 20, 2024

Aclaris Therapeutics (NASDAQ:ACRS) Upgraded by Jefferies Financial Group to “Buy” Rating - Defense World

Nov 20, 2024
pulisher
Nov 20, 2024

Aclaris stock sees over 120% upside potential with bolstered immunology assets - Investing.com India

Nov 20, 2024
pulisher
Nov 20, 2024

Aclaris Therapeutics Enters Exclusive Agreements and Announces Private PlacementWAYNE, Pa., Nov. 16, 2024 /PRNewswire/ — Aclaris Therapeutics, Inc. (NASDAQ: ACRS) has recently entered into significant agreements and a private placement. On Nov - Defense World

Nov 20, 2024
pulisher
Nov 20, 2024

Aclaris Therapeutics (NASDAQ:ACRS) Raised to “Overweight” at Piper Sandler - Defense World

Nov 20, 2024
pulisher
Nov 19, 2024

Aclaris Therapeutics upgraded to Buy from Neutral at BTIG - Yahoo Finance

Nov 19, 2024
pulisher
Nov 19, 2024

S&P 500 Financials [Sector] (SRFI) QuotePress Release - The Globe and Mail

Nov 19, 2024
pulisher
Nov 19, 2024

TSX Composite High Beta Index (TXHB) QuotePress Release - The Globe and Mail

Nov 19, 2024
pulisher
Nov 19, 2024

TSX Venture Composite Index (JX) QuotePress Release - The Globe and Mail

Nov 19, 2024
pulisher
Nov 19, 2024

Aclaris Stock Soars As Analysts See Fresh Momentum After Strategic Review And Encouraging Promising Pipeline Developments - Benzinga

Nov 19, 2024
pulisher
Nov 19, 2024

Aclaris Therapeutics Up 53%; Analysts' Target Boosts Follow Monday License News - MarketWatch

Nov 19, 2024
pulisher
Nov 19, 2024

Aclaris stock soars for second day on licensing deal, analyst upgrades (NASDAQ:ACRS) - Seeking Alpha

Nov 19, 2024
pulisher
Nov 19, 2024

Aclaris gains global rights to Biosion's inflammatory treatment candidates By Investing.com - Investing.com UK

Nov 19, 2024
pulisher
Nov 19, 2024

Aclaris Therapeutics Stock Surges On Licensing Deal, $80 Million Private Placement: Retail Sentiment Jumps - MSN

Nov 19, 2024
pulisher
Nov 19, 2024

Stock Market News: Aclaris Therapeutics gains over 55% while Exicure increases almost 31% during mid day trading - Business Upturn

Nov 19, 2024
pulisher
Nov 19, 2024

This BioNTech Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday - Benzinga

Nov 19, 2024
pulisher
Nov 19, 2024

Aclaris back on track with new money and promising deal - The Pharma Letter

Nov 19, 2024
pulisher
Nov 19, 2024

Aclaris Therapeutics secures global rights to Biosion’s antibodies - Yahoo Finance

Nov 19, 2024
pulisher
Nov 19, 2024

ACRS Stock Up on Licensing Deal With Biosion for Two Immunology Drugs - Yahoo Finance

Nov 19, 2024
pulisher
Nov 19, 2024

Aclaris Therapeutics (NASDAQ:ACRS) Upgraded at Leerink Partners - MarketBeat

Nov 19, 2024
pulisher
Nov 19, 2024

Leerink Partners Upgrades Aclaris Therapeutics (ACRS) - MSN

Nov 19, 2024
pulisher
Nov 19, 2024

Aclaris Therapeutics upgraded to Outperform from Market Perform at Leerink - TipRanks

Nov 19, 2024
pulisher
Nov 19, 2024

Aclaris Therapeutics (NASDAQ:ACRS) Raised to Buy at Jefferies Financial Group - MarketBeat

Nov 19, 2024
pulisher
Nov 19, 2024

Jefferies says buy this pharmaceutical play, sees more than 100% upside from here - Head Topics

Nov 19, 2024
pulisher
Nov 19, 2024

Aclaris to license Biosion’s two biologics assets for up to $940m - World Pharmaceutical Frontiers

Nov 19, 2024
pulisher
Nov 19, 2024

Aclaris stock boosted by BTIG on transformative AD drug acquisition and outlook - Investing.com

Nov 19, 2024
pulisher
Nov 19, 2024

Aclaris shares retain Hold rating at Stifel, price target reaffirmed - Investing.com

Nov 19, 2024
pulisher
Nov 18, 2024

More bispecific deals in China: Aclaris/Biosion, Ouro/Keymed, Avenzo/VelaVigo - BioCentury

Nov 18, 2024
pulisher
Nov 18, 2024

Aclaris Therapeutics, Inc. announced that it expects to receive funding from a group of investors - Marketscreener.com

Nov 18, 2024
pulisher
Nov 18, 2024

Aclaris Therapeutics (ACRS): Strategic Alliance with Biosion Ignites 53% Stock Surge - BP Journal

Nov 18, 2024
pulisher
Nov 18, 2024

HCW Biologics Inc. (HCWB): A Strategic Leap with Worldwide Licensing Agreement Sends Stock Up Over 310% - BP Journal

Nov 18, 2024
pulisher
Nov 18, 2024

Aclaris stock rallies 53% amid licensing deal, Piper upgrade (NASDAQ:ACRS) - Seeking Alpha

Nov 18, 2024
pulisher
Nov 18, 2024

Aclaris Therapeutics upgraded to Overweight from Neutral at Piper Sandler - TipRanks

Nov 18, 2024
pulisher
Nov 18, 2024

Aclaris secures $80 million in private stock sale By Investing.com - Investing.com Canada

Nov 18, 2024
pulisher
Nov 18, 2024

Aclaris shares surge on licensing deal valued at up to nearly $1 billion - The Business Journals

Nov 18, 2024
pulisher
Nov 18, 2024

Aclaris (ACRS) Gains Momentum With Strategic Business Expansion - Stocks Telegraph

Nov 18, 2024
pulisher
Nov 18, 2024

Biosion sells antibody rights to Aclaris in $940M deal - BioWorld Online

Nov 18, 2024
pulisher
Nov 18, 2024

Stock market today: Fate Therapeutics gains 70.79% whereas SiNtx Technologies rose by 38.73% in early trading - Business Upturn

Nov 18, 2024
pulisher
Nov 18, 2024

Biosion Announces Exclusive, Global License Agreement with Aclaris Therapeutics on two potential - Digital More

Nov 18, 2024
pulisher
Nov 18, 2024

Aclaris secures $80 million in private stock sale - Investing.com

Nov 18, 2024

Aclaris Therapeutics Inc Azioni (ACRS) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading

Aclaris Therapeutics Inc Azioni (ACRS) insider trading

Commercio interno Relazione Data Transazione Costo #Azioni Valore ($) #Azioni Totale
Walker Neal
INTERIM PRESIDENT AND CEO
Aug 09 '24
Option Exercise
0.72
43,548
31,355
1,356,153
Leonard Braden Michael
10% Owner
Aug 05 '24
Buy
1.24
206,025
256,357
14,250,000
Leonard Braden Michael
10% Owner
Aug 02 '24
Buy
1.29
167,544
216,400
14,043,975
Leonard Braden Michael
10% Owner
Jul 30 '24
Buy
1.30
173,730
226,370
13,776,421
Leonard Braden Michael
10% Owner
Jul 31 '24
Buy
1.33
100,000
132,640
13,876,421
Leonard Braden Michael
10% Owner
Jul 18 '24
Buy
1.30
130,317
169,555
13,578,286
Leonard Braden Michael
10% Owner
Jul 22 '24
Buy
1.33
17,716
23,557
13,602,691
Leonard Braden Michael
10% Owner
Jul 19 '24
Buy
1.30
6,689
8,696
13,584,975
Leonard Braden Michael
10% Owner
Jul 03 '24
Buy
1.16
143,288
166,071
13,324,952
Leonard Braden Michael
10% Owner
Jul 05 '24
Buy
1.15
123,017
141,334
13,447,969
diagnostics_research LH
$239.53
price up icon 0.74%
$170.39
price up icon 1.49%
$130.78
price down icon 0.68%
diagnostics_research WAT
$366.26
price up icon 2.36%
diagnostics_research MTD
$1,186.88
price up icon 1.66%
$408.36
price down icon 1.66%
Capitalizzazione:     |  Volume (24 ore):